NFE2L2 and nonpapillary renal cell carcinoma: Yamaguchi et al. studied the association between ccRCC and SNP rs6721961 in the promoter of NFE2L2 gene and demonstrated that both homo- and heterozygosity cause increased expression of the protein associated with a worse response to VEGF-targeted therapy and a shorter overall survival [113].